ctDNA From Blood Equals or Bests Tissue-Based Tests in Triple Negative Breast Cancer

This blood-based ctDNA test helped predict recurrence as quickly or sooner than alternative, tumor biopsy-based tests. This could be a significant step forward in follow-up of patients with this particularly deadly form of breast cancer.